- Outsourcing in the biotech and pharma industry continues unabated, projected to reach almost 50% penetration next year.
- This is boosting contract research organisations (CRO) like $IQV $LH
- Interestingly consolidation has been a big feature of the industry, and this expert call (professional investors can sign up for free two weeks to access) from Stream suggests more is to come.
A really interesting insight about biotech and pharma. I guess CROs are designed to reduce costs for companies developing new medicines and drugs in niche markets this appears to be the commercial way forward for them and will definitely reduce the need for in-house trials or research.
Thanks for sharing Snippet